Basel, Switzerland, 24-11-2014 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the U.S. Food and Drug Administration (FDA)…
Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data…
BAL30072 current multiple ascending dose study reached maximum tolerated dose Further development, including combination studies with carbapenems, planned under BARDA…